<DOC>
	<DOCNO>NCT01705002</DOCNO>
	<brief_summary>This Phase I , multi-center , Dose-Escalating , Safety Study Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug ( PL-MLP , PROMITIL ) Cancer Patients Solid Tumors . The study comprise : Escalated cohort A-H : 27 male female participant , age 18-80 , BMI 18-36 diagnose inoperable , recurrent metastatic malignant solid tumor , deem incurable , fail respond standard therapy standard therapy available . Eligible subject assign , successively order accrual , one eight cohort , receive escalate dos intravenously infuse PROMITIL . PROMITIL administer intravenous infusion . Dose escalation proceed absence dose-limiting toxicity ( DLT ) . For purpose , cohort begin first cycle PROMITIL cohort precede successfully complete first 4-week cycle without sign DLT . Expanded cohort : 17 adult patient metastatic CRC . The purpose expand cohort evaluate safety Promitil search sign antitumor activity Promitil specific patient population . Combination Cohort ( Promitil concomitantly Capecitabine ) : 23 adult patient metastatic CRC .</brief_summary>
	<brief_title>Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug ( PROMITIL ) Cancer Patients With Solid Tumors .</brief_title>
	<detailed_description>For cohort , PROMITIL administer intravenous infusion initial rate 0.25mg/min follow gradual increase maximal rate 2mg/min completion dosing , absence infusion reaction establish line update version IFU available study . For subject , subsequent dose take place 28 day previous treatment , provide deemed fit dose . Patients return study center day 8 , 15 , 22 cycle 1 , day 15 cycle 2 3 , monitor assessment . All patient followed-up survival post-Promitil treatment . Patients receive 3 cycle PROMITIL follow PD .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>1 . Patients diagnose inoperable , recurrent metastatic malignant solid tumor , deem incurable , either : Failed respond standard therapy For standard therapy available Refuse receive standard therapy 2 . Histologically cytologically confirm diagnosis solid tumor file . 3 . Age 1880 year 4 . BMI : 1836 5 . ECOG Performance Status ≤ 2 6 . Estimated life expectancy least 3 month 7 . Adequate bone marrow function ( absolute neutrophil count ≥1500/mm3 , hemoglobin ≥9.5 g/dl , HgbA1C≤7 % , platelet count ≥100,000/mm3 ( 8 . Adequate liver function ( serum bilirubin ≤2.0 mg/100 ml ; alanine aminotransferase ≤2× ULN ) 9 . Adequate renal function ( serum creatinine ≤1.5 mg/100 ml creatinine clearance ≥45 ml/min/1.73m2 ) 10 . No prior intravenous treatment MitomycinC either alone combination 11 . No myelosuppressive treatment within 4 week start study drug . 12 . No anticancer treatment within 2 week start study drug 13 . No prior extensive radiotherapy ( e.g. , whole pelvis total neuroaxis great 50 % neuroaxis , whole abdomen , whole body halfbody ) bone marrow transplantation high dose chemotherapy and/or total body irradiation . Reirradiation field abdomen/pelvis consider extensive radiotherapy , exclude patient study . 14 . Women child bear potential practicing acceptable method birth control . 15 . Understanding study procedure willingness comply entire length study give write informed consent . 16 . Additional criterion Expanded Cohort : Patients histologically cytologically confirm recurrent and/or metastatic measurable nonmeasurable CRC , tissue cytological diagnosis cancer file . 17 . Patients receive past treatment oxaliplatin , irinotecan fluopyrimidinebased chemotherapy , , case Kras wild type tumor , receive antiEGFR antibody ( Cetuximab , Panitumumab ) . Patients demonstrate either progression intolerance treat . Prior treatment Bevacizumab allow require . 18 . A ≥ 21 day treatmentfree interval chemotherapeutic treatment , exception Capecitabine biological therapy , ≥14day treatmentfree interval suffice . ( also relevant patient Combination Cohort currently take Capecitabine prior enter study ) . 19 . Additional criterion Combination Cohort : Clinical decision make initiate treatment Capecitabine prior enrollment study . Treatment Capecitabine start either prior sign ICF . 1 . Known hypersensitivity study drug component 2 . CHF ( NYHA = Class IV ) LVEF≤40 % 3 . COPD &gt; Stage 3 ( FEV1 &lt; 50 % , FEV1/FVC &lt; 70 % ) ; 4 . Cirrhosis ( ChildPugh Class C score ) ; 5 . Serum Albumin level &lt; 3 g/dl 6 . Any severe concurrent disease judgment investigator would make subject inappropriate entry study 7 . History human immunodeficiency virus ( HIV ) infection 8 . History chronic active hepatitis include subject carrier hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . 9 . Presence uncontrolled infection . 10 . Evidence active bleeding bleed diathesis 11 . Brain metastasis symptomatic patient require ≥4 mg dexamethasone/day . However , patient treat brain metastasis surgery radiation stable symptomfree ( &lt; 4 mg dexamethasone/day ) minimum period 4 week posttreatment eligible . 12 . Pregnant lactate 13 . Treatment investigational drug within 14 day start study drug nonmyelosuppressive agent , within 28 day start study drug myelosuppressive agent . 14 . Additional criterion Expanded Cohort : Patients prior treatment Regorafenib exclude enter Expanded Cohort . 15 . Additional criterion Combination cohort : Uncontrolled ascites ( define 2 palliative tap last 30 day screen ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>phase 1</keyword>
	<keyword>dose escalate</keyword>
	<keyword>prodrug</keyword>
	<keyword>mitomycin C</keyword>
	<keyword>Capecitabine</keyword>
</DOC>